

Status: Currently Official on 16-Feb-2025  
 Official Date: Official as of 01-Aug-2017  
 Document Type: USP Monographs  
 DocId: GUID-C22FB4A4-B358-49BF-996E-8198E9C8F208\_1\_en-US  
 DOI: [https://doi.org/10.31003/USPNF\\_M63020\\_01\\_01](https://doi.org/10.31003/USPNF_M63020_01_01)  
 DOI Ref: 80pii

© 2025 USPC  
 Do not distribute

## Phenazopyridine Hydrochloride Tablets

### DEFINITION

Phenazopyridine Hydrochloride Tablets contain NLT 90.0% and NMT 110.0% of the labeled amount of phenazopyridine hydrochloride ( $C_{11}H_{11}N_5 \cdot HCl$ ).

### IDENTIFICATION

- **A.** The UV spectrum of the phenazopyridine peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.
- **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

### ASSAY

#### • PROCEDURE

**Solution A:** 20 mM ammonium acetate in water

**Solution B:** Acetonitrile

**Mobile phase:** See [Table 1](#).

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	95	5
2	95	5
15	50	50
20	50	50
28	30	70
33	30	70
35	95	5
40	95	5

**Diluent:** Acetonitrile and water (10:90)

**Standard solution:** 0.03 mg/mL of [USP Phenazopyridine Hydrochloride RS](#) in *Diluent*

**Sample stock solution:** Nominally 0.3 mg/mL of phenazopyridine hydrochloride from NLT 20 finely powdered Tablets in *Diluent*, prepared as follows. Transfer a suitable amount of the powder to a suitable volumetric flask. Add *Diluent* equivalent to 75% of the flask volume and sonicate for 15 min. Allow the solution to cool to room temperature, dilute with *Diluent* to volume, and centrifuge.

**Sample solution:** Nominally equivalent to 0.03 mg/mL of phenazopyridine hydrochloride in *Diluent* from the *Sample stock solution*

### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 280 nm. For *Identification A*, use a diode array detector in the range of 200–600 nm.

**Column:** 4.6-mm × 25-cm; 5-μm packing L1

**Flow rate:** 1 mL/min**Injection volume:** 20  $\mu$ L**System suitability****Sample:** Standard solution**Suitability requirements****Tailing factor:** NMT 2.0**Relative standard deviation:** NMT 1.0%**Analysis****Samples:** Standard solution and Sample solutionCalculate the percentage of the labeled amount of phenazopyridine hydrochloride ( $C_{11}H_{11}N_5 \cdot HCl$ ) in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

 $r_U$  = peak response from the Sample solution $r_S$  = peak response from the Standard solution $C_S$  = concentration of [USP Phenazopyridine Hydrochloride RS](#) in the Standard solution (mg/mL) $C_U$  = nominal concentration of phenazopyridine hydrochloride in the Sample solution (mg/mL)**Acceptance criteria:** 90.0%–110.0%**PERFORMANCE TESTS**• [Dissolution \(711\)](#)**Medium:** Water; 900 mL**Apparatus 2:** 50 rpm**Time:** 45 min**Standard solution:** [USP Phenazopyridine Hydrochloride RS](#) in Medium**Sample solution:** Filter portions of the solution under test and suitably dilute with Medium to a concentration that is similar to that of the Standard solution.**Instrumental conditions****Mode:** UV**Analytical wavelength:** 422 nm**Analysis****Samples:** Standard solution and Sample solutionCalculate the quantity of phenazopyridine hydrochloride ( $C_{11}H_{11}N_5 \cdot HCl$ ) dissolved by using UV absorption from the Sample solution in comparison with the Standard solution.**Tolerances:** NLT 75% (Q) of the labeled amount of phenazopyridine hydrochloride ( $C_{11}H_{11}N_5 \cdot HCl$ ) is dissolved.• [Uniformity of Dosage Units \(905\)](#): Meet the requirements**IMPURITIES**• [Organic Impurities](#)**Solution A, Solution B, Mobile phase, and Diluent:** Proceed as directed in the Assay.**Sensitivity solution:** 0.25  $\mu$ g/mL of [USP Phenazopyridine Hydrochloride RS](#) in Diluent**Standard solution:** 0.001 mg/mL of [USP Phenazopyridine Hydrochloride RS](#) in Diluent**Sample solution:** Nominally 0.5 mg/mL of phenazopyridine hydrochloride from NLT 20 finely powdered Tablets in Diluent, prepared as follows.

Transfer a suitable amount of the powder to a suitable volumetric flask. Add Diluent equivalent to 60% of the flask volume and sonicate for 15 min. Allow the solution to cool to room temperature and dilute with Diluent to volume. Centrifuge the solution and dilute the supernatant with Diluent to obtain 0.5 mg/mL of phenazopyridine hydrochloride.

**Chromatographic system:** Proceed as directed in the Assay except for the Detector.**Detector:** UV 240 nm**System suitability****Samples:** Sensitivity solution and Standard solution**Suitability requirements****Tailing factor:** NMT 1.5 for the phenazopyridine peak, Standard solution**Relative standard deviation:** NMT 3.0% for the phenazopyridine peak, Standard solution

**Signal-to-noise ratio:** NLT 30 for the phenazopyridine peak, *Sensitivity solution*

### Analysis

**Samples:** Standard solution and Sample solution

Calculate the percentage of any individual unspecified impurity in the portion of the Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of each individual unspecified impurity from the *Sample solution*

$r_S$  = peak response of phenazopyridine from the *Standard solution*

$C_S$  = concentration of [USP Phenazopyridine Hydrochloride RS](#) in the *Standard solution* (mg/mL)

$C_U$  = nominal concentration of phenazopyridine hydrochloride in the *Sample solution* (mg/mL)

**Acceptance criteria:** See [Table 2](#). Disregard any impurity peaks less than 0.05%.

**Table 2**

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
2,6-Diaminopyridine <sup>a</sup>	0.37	—
Phenazopyridine	1.00	—
Individual unspecified impurity	—	0.2
Total impurities	—	2.0

<sup>a</sup> For identification only. These are process impurities monitored in the drug substance and are not included in the total impurities.

### ADDITIONAL REQUIREMENTS

• **PACKAGING AND STORAGE:** Preserve in tight containers. Store at controlled room temperature.

• [USP REFERENCE STANDARDS \(11\)](#)

[USP Phenazopyridine Hydrochloride RS](#)

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
PHENAZOPYRIDINE HYDROCHLORIDE TABLETS	<a href="#">Documentary Standards Support</a>	SM22020 Small Molecules 2
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM22020 Small Molecules 2

**Chromatographic Database Information:** [Chromatographic Database](#)

### Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 41(2)

**Current DocID: GUID-C22FB4A4-B358-49BF-996E-8198E9C8F208\_1\_en-US**

**DOI:** [https://doi.org/10.31003/USPNF\\_M63020\\_01\\_01](https://doi.org/10.31003/USPNF_M63020_01_01)

**DOI ref:** [80pii](#)